Correction to “Therapeutic efficacy of lenvatinib as third‐line treatment after regorafenib for unresectable hepatocellular carcinoma progression”

Hiraoka A, Kumada T, Hatanaka T, Tada T, Kariyama K, Tani J, et al. Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. Hepatology Research. 2021; 51: 880–9. https://doi.org/10.1111/hepr.13644. In the “Methods” section of the abstract, the text “From June 2017 to October 2020, 63 patients with Child–Pugh A and treated with regorafenib followed by sorafenib were enrolled…” was incorrect. This should have read: “From June 2017 to October 2020, 63 patients with Child–Pugh A and treated with sorafenib followed by regorafenib were enrolled…” We apologize for this error.